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cense. httpAbstract Background: Hepatocelluar carcinoma (HCC) is a major health problem in Egypt as
well as in many countries. Transarterial chemoemoblization (TACE) is a treatment modality appli-
cable to locally advanced HCC beyond surgery or ablative therapies and is associated with survival
improvements. The aim of this study was to assess the outcomes of TACE in our center over the
past four years.
Methods: This is a retrospective cohort study that included 221 patients with locally advanced
HCC treated with TACE in a single center between the years 2007 and 2010. The median age
was 57 years with male predominance. Liver cirrhosis, viral hepatitis and Bilharziasis were encoun-
tered in 64%, 31% and 8% of patients, respectively. Abdominal pain was the most common pre-
senting symptom (67%). Most cases were diagnosed based on radiology (57%) with a TNM
stage I or II (73%) and a median AFP value of 150 ng/mL.
Results: 221 patients received 440 cycles of TACE with a median of 2 cycles per patient. Cisplatin
and doxorubicin (50 mg per cycle, each) were the most commonly used drugs. Impaired liver func-
tion was the most common toxicity. Liver cell failure occurred in 17% of patients. An objective
tumor response was achieved in 44% of cases. The median overall survival (OS) was 16 months
(95% CI, 13–19 months) and the median progression free survival (PFS) was 6 months (95% CI,rtment of Medical Oncology/
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144 A.A. Zeeneldin et al.4.3–7.8 months). Responding patients, Child-Pugh class A and patients receiving standard doses of
chemotherapy had a signiﬁcantly better OS than their counterparts. Only Child-Pugh class A was
associated with signiﬁcantly longer PFS (p< 0.001).
Conclusion: TACE produces reasonable responses and fair survival rates in locally advanced HCC
but with noticeable toxicities. Proper patients’ selection and prompt liver support are mandates for
improving TACE outcomes.
ª 2013 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
Open access under CC BY-NC-ND license.Background
Hepatocellular carcinoma (HCC) is the most common form of
primary liver cancer. Globally, liver cancer is the 5th and 7th
most common cancer in men and women, respectively. Most
of HCC burden lies in developing countries. The regions of
high incidence include Eastern and South-Eastern Asia, Mid-
dle and Western Africa. Worldwide, it is the third most com-
mon cause of cancer deaths [1]. In many Egyptian regional
registries, liver cancer is the ﬁrst cancer in men and the second
in women [2]. In Gharbiah population-based cancer registry,
liver cancer represents 12.7% of male cancers and 3.4% of fe-
male cancers [3].
Risk factors for HCC are many and include viral hepatitis
B and C (HBV and HCV, respectively), cirrhosis, aﬂatoxins,
alcohol, smoking and male gender [4]. These risk factors vary
among countries, but chronic infections with HBV and HCV
are the most important precursors for HCC development on
a global scale. Together, HBV and HCV account for over
80% of liver cancer cases worldwide [5]. In Egypt, HCV is
the main risk factor for HCC where 71% of HCC cases are po-
sitive for anti-HCV antibodies [6]. The Egyptian Ministry of
Health estimated that the incidence of HCV infection among
Egyptians is 6.9/100,000 persons per year [7]. The 2008 Egypt
Demographic and Health survey (EDHS) showed that almost
15% of the 11,000 tested populations had HCV antibodies in
their blood indicating exposure and 10% were positive for
HCV RNA test indicating active infection. Prevalence was
higher among rural than urban areas, among men than women
and among older than younger populations [8].
Surgical resection or liver transplantation provides the best
results in appropriate candidates. When surgery is precluded,
local non-surgical therapies like intra-lesional ethanol injection
or radiofrequency thermal ablation can be used for smaller tu-
mors. Transarterial chemoembolization (TACE) provides
modest survival advantage in patients with preserved liver
function (Child-Pugh class A) and larger or multinodular tu-
mors. TACE can be used as holding or bridging therapy prior
to liver resection or transplantation. TACE may also be used
as a sole therapy for advanced liver tumors not eligible for sur-
gery [9]. Of the different systemic therapies, only the oral mult-
ikinase inhibitor Sorafenib showed a clear survival beneﬁt in
advanced HCC [10]. Sorafenib plus doxorubicin compared
with doxorubicin monotherapy resulted in signiﬁcantly greater
median time to progression, overall survival, and progression-
free survival [11].
It is not clearly known whether TACE in Egyptian HCC
patients produces equivalent outcomes to those reported in
international studies. The aim of this study was to evaluate
TACE as a method of therapy in advanced HCC in Egyptian
patients regarding prevailing indications, drugs used, safety
and efﬁcacy of the procedure.Patients and methods
This is a retrospective cohort study that included patients diag-
nosed with advanced HCC and treated with TACE at the Na-
tional Cancer Institute (NCI), Cairo University, between
January 2007 and December 2010. The study was approved
by the NCI Institutional Review Board. The medical records
of eligible patients were retrieved and relevant information
extracted.
The primary endpoint was overall survival (OS). Secondary
endpoints were progression free survival (PFS), response rates
(RR) and toxicity of the TACE procedure. OS was deﬁned as
the time in months from the date of diagnosis until death or
last follow up. PFS was deﬁned as the time from ﬁrst TACE
until tumor progression, clinical deterioration, death or last
follow up. Tumors were staged according to the AJCC Cancer
Staging Manual, 6th edition [12]. Response was assessed fol-
lowing each cycle and prior to the next cycle. Responses were
assessed using the RECIST V1.0 criteria [13] while TACE tox-
icities were graded according to CTCAE v3.0 [14].
Statistical analyses were performed using SPSS software
version 15, Chicago, IL. Numerical variables were presented
as means and standard deviations (SD) or medians and ranges
and groups were compared using the student t-test or Mann–
Whitney U test. Survival was estimated using the Kaplan–Me-
ier method and groups were compared using the log–rank test.
A p value 60.05 was considered signiﬁcant.
Baseline clinico-pathological characteristics
The study included 221 locally advanced HCC patients whose
ages ranged between 38 and 84 years with a mean of 57 years
(Table 1). Most cases (57%) were diagnosed based on classic
enhancement on radiology [15,16] and histological conﬁrma-
tion was available for 43% of cases. Elevated AFP
(>200 ng/dL) supplemented the diagnosis in 29% of cases.
Male to female ratio was 6.4:1. Cirrhosis and viral hepatitis
were documented in 64% and 32% of patients, respectively.
HBV infection was encountered in 1/71 patients (1.4%) and
the remaining 70 patients (98.6%) had HCV infection. A past
history suggestive of Bilharziasis was encountered in 8 patients
(4%), only. Of 221 patients, 40 (18%) had concomitant general
disease; mainly DM (n= 18) followed by hypertension
(n= 9). Among 130 patients with documented presenting
symptoms, pain was encountered in 87 patients (67%). Most
patients had an ECOG performance status (PS) of 2 and a
Child-Pugh class B. The median Child-Pugh score was 7
(range, 5–9). In 81/94 patients with histological proof, the most
common histological grade was grade II (69%). Single tumors
were encountered in 51% of cases. The median maximum
dimension of the dominant lesion was 6 cm (range, 1.2–
19 cm). T1 was encountered in 55% of cases. The commonest
Table 1 Clinico-pathological characteristics of 221 patients with advanced HCC treated with TACE.
Characteristics Subgroups Number (%)
Age (years) Mean ± SD 57 ± 8.4
Sex Male 191 (86)
Female 30 (14)
Predisposing liver disease Cirrhosis 142 (64)
Viral hepatitis 71 (32)
Bilharziasis 8 (4)
Co-morbidities 40 (18)
Presentation (n= 130a) Pain 87 (67)
Asymptomatic 17 (13)
Recurrence 11 (8)
Ascites 6 (5)
others 9 (7)
ECOG Performance status (n= 207a) 0 15 (7)
1 25 (12)
2 167 (81)
Child-Pugh class (n= 214a) A 100 (47)
B 114 (53)
Basis of diagnosis Histology 94 (43)
Radiology and AFP 65 (29)
Radiology only 62 (28)
Histological grade (n= 81) I 17 (21)
II 56 (69)
III 8 (10)
Number of lesions (n= 213) Single 109 (51)
Multiple 104 (49)
Primary tumor (T) stage (n= 193a) T1 106 (55)
T2 41 (21)
T3 46 (24)
Vascular invasion (n= 213a) Present 6 (3)
Regional Lymph node involvement (n= 212a) N0 201 (95)
N1 11 (5)
TNM stage (n= 189a) I 95 (50)
II 44 (23)
III 36 (19)
IV 14 (8)
Okuda stage (n= 193a) I 45 (23.3)
II 147 (76.2)
III 1 (0.5)
HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; SD, standard deviation; TNM, tumor, node and metastases; AFP,
alfa-fetoprotein.
a The rest of the 221 cases had missing data.
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node, vascular invasion and distant metastasis were found in
a minority (5%, 3% and 2%, respectively) and the liver was
the burdensome site in all of these cases. The commonest Oku-
da stage was II (76%). The median Okuda score was 1 (range,
0–3). The Median Cancer of the Liver Italian Program (CLIP)
score was 2 (range, 0–4). The median baseline value for AFP
was 150 (range, 1–283,903) ng/mL, for INR 1.1 (range, 1.0–
1.9), for Hemoglobin 13 (range, 7.4–18.7) g/dL, for WBC’s
5.7 (range, 2.6–18.7) 1000 cell/mL, and for platelets 150 (range,
40–740) 1000 cell/mL.Results
TACE treatments
The 221 patients included in the study received 440 cycles of
TACE (Table 2). The median number of TACE sessions per
patient was 2 (range, 1–8). Almost half of the patients (50%)
received one cycle only and 3 quarters did not receive more
than 2 cycles. Cisplatin, doxorubicin, and epirubicin were used
in 220, 213 and 8 patients (99.5%, 96% and 4%, respectively).
Except one patient who received doxorubicin only, all received
Table 2 Details of TACE treatments in 221 patients with
advanced HCC.
Item Subgroup Number (%)
Number of TACE cycles Total number 440 (100)
Median (range) 2 (1–8)
TACE drugs Single agent doxorubicin 1 (0.5)
Combination of doxorubicin
and cisplatin
212 (95.9)
Combination of epirubicin
and cisplatin
8 (3.6)
TACE drug doses Standard 214 (97)
High 7 (3)
Toxicities (n= 89a) Clinical 24 (27)
Laboratory 47 (53)
Clinical and laboratory 18 (20)
Responses (n= 151a) CR 29 (19.2)
PR 37 (24.5)
SD 16 (10.6)
PD 69 (45.7)
HCC, hepatocellular carcinoma; TACE, transarterial chemoemb-
olization; CR, complete response; PR, partial response; SD, stable
disease; PD, progressive disease.
a The rest of 221 cases had missing data.
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A ﬁxed dose of 50 mg cisplatin and 50 mg doxorubicin or epi-
rubicin was used in 214/221 patients (97%) and a higher dose
(100 mg) of cisplatin and/or doxorubicin/epirubicin was used
in 7 patients (3%). The embolic material used was Lipiodol
in all cases while gelfoam was used in addition to lipiodol in
about one third of cases especially those with large tumor size.
Super selection using microcatheter techniques were used in
60% of cases but not in old cases.
TACE toxicities
Out of 221 patients, 89 (40%) were documented to have evi-
dence of toxicities either clinical, laboratory or both (Table 2).
Clinical toxicities (fever, abdominal pain, nausea) were
encountered in 47% of patients (27% as the sole toxicity and
20% combined with lab toxicities). Manifestations of liver cell
impairment (ascites, jaundice, bleeding) occurred in 36/42 pa-
tients (87%). It progressed to overt liver cell failure in 15 pa-
tients (17%). Venous thrombosis occurred in 3/42 patients (2
patients with portal vein thrombosis and one case with hepatic
vein thrombosis). Diarrhea and febrile neutropenia were
encountered in one patient each. Laboratory toxicities were
encountered in 73% of patients (53% as the sole toxicity and
20% combined with clinical toxicities). The main laboratory
toxicities were elevated liver enzymes in 46/65 patients
(71%), elevated bilirubin in 11/65 patients (17%), thrombocy-
topenia in 4/65 patients (6%), decreased serum albumin and
elevated serum creatinine in 2 patients (3%), each. Most of
the clinical and laboratory toxicities were grade 3 or 4 that
mandated cessation of TACE treatments in 30 patients
(33.7%). Mortality attributable to TACE complications was
encountered in 19 patients due to liver cell failure in 17 pa-
tients, febrile neutropenia in one patient and acute renal failure
in one patient. Toxicities were encountered more in thepatients who received higher doses of drugs and with higher
baseline Child-Pugh score.
Tumor response to TACE
Response assessment was documented in 151/211 patients
(68%), the remaining 70 patients were lost to follow up before
response assessment. Tumor response was achieved in 43.7%
of the assessed cases that was complete in 19.2% and partial
in 24.5% of patients. The disease was stable in 10.6% of pa-
tients and 45.7% of patients suffered progressive disease that
was commonly local in the liver and less commonly regional
(LN) or distant (74%, 7% and 19%).
Overall survival
As documented in the last visit and after a median follow up
period of 18 months (range, 1–66 months), 104/221 patients
(47%) were alive and 117/221 (53%) were dead. The median
OS was 16 months (95% CI, 13–19) (Figure 1). The 1-, 2-
and 3-year OS rates ± standard errors were 57.8%± 3.7%,
33.6%± 4.3% and 22.0%± 4.4%, respectively. The impact
of various prognostic factors on OS is shown in Table 3.
Responding patients (CR or PR), Child-Pugh class A, and pa-
tients who received standard doses of chemotherapy had a sig-
niﬁcantly better OS (p< 0.05 for all). AFP < 200 ng/mL was
associated with better OS but was not statistically signiﬁcant.
Age, gender, PS, TNM staging, number of lesion and number
of sessions had no impact on OS.
Progression free survival
The median progression free survival was 6 months (95% CI,
4.3–7.8) (Figure 2). The 1- and 2-year PFS rates ± standard
error were 35.8%± 3.9% and 13.1%± 3.6%, respectively.
Child-Pugh A was associated with signiﬁcantly longer PFS
(Table 3). Male gender, AFP < 200 ng/mL, and patients
who received only one TACE session were associated with
longer but not statistically signiﬁcant PFS.Discussion
The liver has a unique dual blood supply from both the portal
vein and the hepatic artery. The normal parenchyma of the li-
ver receives two thirds of its necessary blood supply from the
portal vein and the remaining from the hepatic artery. How-
ever, it is well known that vascularization of HCC is mostly
dependent on the hepatic artery [17]. This characteristic of
HCC not only justiﬁes the diagnostic use of contrast enhanced
CT and MRI, but also provides a basic rationale for transar-
terial therapy as an effective treatment of HCC [18]. The goals
of TACE are to deliver concentrated chemotherapy directly to
the tumors and to reduce the blood supply to the tumor, caus-
ing ischemic necrosis [19].
The mean age of 57 years and the male predominance in the
current study mimics HCC population in Egypt, at large [20–
22] as well as some other countries [23]. The male predomi-
nance may be explained by differences in exposure to risk fac-
tors. However, sex hormones have been linked with HCC
development [24,25].
Figure 1 Overall survival of 221 patients with locally advanced
hepatoma receiving Transarterial chemoembolization (continuous
line is the main survival curve, dotted curves represent the upper
and lower boundary of the 95% conﬁdence interval).
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USA, Saudi Arabia and Egypt, HCV is the main risk factor
for HCC. With the implementation of vaccination programs
against HBV, the importance and the prevalence of HCV as
an etiological factor for HCC is increasing [1]. In Italy, for
example, the incidence of HCV as a risk factor was 50.4%
while HBV was 7.7% [26]. Similarly, incidence of HBV and
HCV was 71% and 15% in HCC patients in India, respectively
[27]. On the other hand, HBV is endemic in China and studies
on HCC in Chinese population showed that the incidence of
HBV was 81% and that of HCV was 4% [23]. In the current
study, viral hepatitis was documented in one third of patients
(71/221) and HCV was predominant (32% of patients)
whereas HBV was encountered only in one patient. HCV pre-
dominance was similar to prior reports from Egypt [28–34].
Despite HCC can develop in absence of cirrhosis, 60–80%
of persons with HCC have underlying cirrhosis, possibly
approaching 90% in countries like the USA [35]. In the current
study, cirrhosis was documented in 64% of cases and this is
lower than reports from countries like Germany [36] and in
the USA [37] where cirrhosis was encountered in more than
90% of HCC patients. We believe this represents underreport-
ing of cirrhosis rather than a true incidence given the retro-
spective nature of the current study.
The mean tumor size in the current study was 6.4 cm which
was similar to the 7 cm size reported by Herber et al. and
Lewandowski et al. [36,37] and smaller than the 10.5 cm re-
ported by Shi et al. [39]. It was larger than the 4.9 CM reported
by Llovet et al. [40]. While this reﬂects variation among trials,
it also emphasized that these patients have advanced disease
beyond surgery or local/ablative therapy.
The objective response rates of TACE have been reported
between 15% and 61% [17,38,40–51] and complete responses
may reach up to 20–35% [52]. In the current study, the re-
sponse rate was 43.7% with CR in 19.2% and PR in 24.5%.
While these ﬁgures go with those mentioned in the literature,
it should be noted that responses were assessable in only
151/221 patients as the remaining 50 patients did not show
up following the 1st TACE mostly due to clinical deterioration
because of TACE toxicities or tumor progression. If these were
considered as non responders, the response rates would be low-
er (66/221, 30%). The fair responses to TACE call for their
integration in the treatment plan for HCC e.g. as a neoadju-
vant measure to be followed by surgery or local ablative
therapies.
TACE is very stressful for HCC patients and can have
plenty of complications particularly with underlying causative
factors (e.g. compromised liver function, main portal vein
thrombosis, biliary tract obstruction, a previous history of bile
duct surgery) or inadvertent techniques (e.g. Lipiodol or che-
motherapeutic overdosage, nonselective TACE or hepatic ar-
tery occlusion with repeated treatments) [17]. The most
common complication is post embolization syndrome (PES)
that occurs in 60–80% of cases and the most serious is hepatic
failure that occurs in a median of 8% of cases [52]. In the cur-
rent study, toxicities of TACE were assessable only in 89 pa-
tients (40% of the total). The reasons for this low reporting
include defective documentation particularly with the retro-
spective nature of the study, the noticeable no-show after the
1st TACE (50/221, 21%) and the split follow up of TACE pa-
tients at NCI between Medical Oncologists and Interventional
radiologist with the latter being involved in the diagnosis andmanagement but with limited access to documentation in the
paper medical records. PES was encountered in all patients
and hepatic failure was documented in 15/89 patients (17%).
The relatively low documentation of toxicities might have con-
tributed to the high rates of PES and liver failure.
Almost half of the patients received one cycle only of
TACE and 3 quarters did not receive more than two cycles.
This may reﬂect the poor tolerance to the procedure as most
of the patients presented with performance status of 2 and half
of them were of the Child-Pugh class B. This highlights the ur-
gent need for proper patient selection to minimize TACE com-
plications and improve its tolerance [17,39].
Some randomized controlled trials [38,47] and meta-analy-
sis [40,53] have demonstrated the effectiveness of TACE on
overall survival with improvement of the two-year survival
rates and increase in the median OS survival compared to pal-
liative care. In the current study, the 1-, 2- and 3-year OS rates
of 58%, 34% and 22%, respectively are similar to the 57%,
31% and 26% respective rates reported by Lo et al. [38] and
ﬁt within 19%-63% 2-year OS rates reported in the meta anal-
ysis by Llovet et al. [40]. However, they were lower than the
82%, 63% and 29% OS rates reported by Llovet [47]. The bet-
ter ﬁgures with Llovet et al. report could be the inclusion of pa-
tients with favorable prognosis than the current study where
the liver tumors are smaller (4.9 cm vs. 6.3 cm), more Child-
Pugh A class patients (79% vs. 47%) and more patients with
PS 0–1 (97.5% vs. 19%). In the current study the median OS
was 16 months, similar to what is reported by several authors
[30–33,38]. However, it was lower than the median of
30 months that is reported by Llovet et al. and Cabibbo
et al. [47,54] and higher than the median of 10.4 months re-
ported by Shi et al. [39]. The main reason for this variation
is the differences in patients’ populations and their disease ex-
tent and the degree of cirrhosis with patients in the current
study having baseline characteristics that confer moderate
prognosis between trials with better and worse survival rates,
as mentioned above.
Similar to Lo et al., Shi et al. and Llovert et al. [38,39,47],
OS was signiﬁcantly longer in patients with Child-Pugh class A
compared to B. This highlights the importance of patient selec-
tion for TACE. Also in agreement with Lo et al. and Ebied
Table 3 Prognostic factors possibly affecting OS and PFS of patients with advanced HCC receiving TACE.
Item Subgroup N OS (months) PFS (months)
Median 95% CI p Median 95% CI p
Age 657 years 115 16 10–22 5 3–7
>57 years 106 17 11–23 0.590 7 6–9 0.705
Sex Male 191 16 13–19 6 4–8
Female 30 11 1–26 0.956 4 1–9 0.214
Grade I 17 19 2–36 19 6–32
II 56 25 18–32 9 4–14
III 8 11 1–24 0.700 4 1–12 0.643
AFP ng/mL <200 100 19 15–23 7 3–11
P200 88 14 8–20 0.212 5 3–7 0.064
PS 0–1 40 16 11–21 4 2–6
2 167 16 11–21 0.937 6 4–9 618
Child-Pugh class A 100 21 16–26 14 10–18
B 114 11 7–15 0.026 4 3–6 <0.001
Number of lesions Single 109 16 9–23 6 4–8
Multiple 104 17 13–21 0.824 6 3–9 0.832
T stage T1 106 16 9–23 6 4–8
T2 41 13 5–21 7 4–10
T3 46 14 4–24 0.832 5 1–14 0.906
Drug doses Standard 214 17 14–20 6 4–8
High 7 6 5–7 0.042 2 - 0.830
Number of TACE cycles 1 110 16 11–21 7 4–10
>1 111 17 12–22 0.280 6 4–8 0.763
Response Responding 66 16 10–22 NA
Non-responding 85 9 6–12 0.002 NA
TNM stage I 95 17 9–25 6 4–8
II 44 16 10–22 7 4–10
III/IV 50 14 3–25 0.740 4 1–7 0.984
LN involvement N0 198 16 12–20 6 4–8
N1 11 16 1–39 0.16 5 1–19 0.865
Metastases M0 205 16 12–19 6 4–8
M1 4 6 4–8 0.46 4 1–8 0.404
OS, overall survival; PFS, progression free survival; HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; CI, 95%
conﬁdence interval; PS, performance status; NA, not applicable, TNM, tumor, node and Metastasis; LN, Lymph node.
148 A.A. Zeeneldin et al.et al. [38,55], OS was signiﬁcantly longer in responding pa-
tients compared to non-responding patients.
The median PFS in this study was 9 months which is rela-
tively similar to a previous TACE report from Egypt where
the median PFS was 32 weeks [56]. Child-Pugh class A was
associated with signiﬁcantly longer PFS than class B.
To the best of our knowledge, the current study is one of
the largest series that reports on TACE. It also reports a com-
mon and mostly uniﬁed practice in the largest Egyptian cancer
center where HCC is prevailing. On the other hand, the retro-
spective nature of the present study has its limitations [57].
However, we have done our maximal efforts to have a well
conducted study that reﬂects the community practice e.g. sur-
vival data were updated using telephone calls to the patients.
Conclusion
TACE produces reasonable responses and fair survival rates in
locally advanced HCC but with noticeable toxicities. Bettercase selection that included patients with adequate liver func-
tion (Child-Pugh A) and good performance status as well as
prompt liver support are mandates for improving TACE out-
comes. Tailoring drug doses to individual patients is advisable.
Less toxic new TACE strategies that may increase efﬁcacy or
decrease toxicity should be explored on a wide scale at the
Egyptian NCI. These include drug-eluting beads and radioac-
tive pharmaceuticals. It is preferable to have TACE patients
admitted for few days following the procedure to observe
and manage complications. The management of HCC patients
should be through a harmonized multidisciplinary service.
Measures to improve documentation of patients’ medical
information in the medical records are urgently advisable.
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